LC
XLRN

Lindbrook Capital’s Acceleron Pharma XLRN Stock Holding History

Lindbrook Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23
Closed -$3K – 2058
2021
Q2 		$3K Buy
23
+15
+188% +$1.89K ﹤0.01% 1538
2021
Q1 		$1K Buy
+8
New +$1.03K ﹤0.01% 1851

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Lindbrook Capital's XLRN Position: Q3 2021 in Review

Lindbrook Capital sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 23 shares — an estimated $3K sold.

Lindbrook Capital first reported a position in XLRN in Q1 2021 and held it in 2 quarters. The position peaked at $3K in Q2 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Lindbrook Capital reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Lindbrook Capital sold 23 Acceleron Pharma shares in Q3 2021, an estimated $3K.
  • Lindbrook Capital first reported a position in Acceleron Pharma in Q1 2021 and held it in 2 quarters.
  • Lindbrook Capital's Acceleron Pharma position peaked at $3K in Q2 2021.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.